logo
Share SHARE
FONT-SIZE Plus   Neg

Bristol-Myers Squibb, Gladstone Institutes Enter 3-yr Discovery Partnership

Bristol-Myers Squibb Co. (BMY) and the Gladstone Institutes announced the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimer's disease.

As per the agreement, Bristol-Myers Squibb will fund Gladstone's research efforts to identify targets that affect Tau dysfunction. Tau is a protein that binds the cell's internal skeleton and may help regulate the activity of brain cells.

In Alzheimer's disease, Tau forms abnormal deposits called neurofibrillary tangles, a hallmark pathology of the disease. By identifying targets that prevent or reverse Tau dysfunction, Bristol-Myers Squibb and Gladstone hope to identify novel therapeutic strategies to modify the course of the disease.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of UBS AG were losing around 5 percent in the morning trading after the Swiss financial services giant reported Tuesday sharply lower profit in its first quarter amid lower net fee and commission as well as trading income. Net interest income, however, improved from last year. Looking ahead, the company said that the ongoing underlying macroeconomic challenges and geopolitical risks ... Asia-focused lender HSBC Holdings Plc reported Tuesday a decline in the first-quarter profit, on weak revenues and net interest income. The results reflected weak performance in all segments and business regions, except Middle East and North Africa as well as CMB. An Illinois woman has filed a lawsuit against Starbucks accusing that the coffee retail giant is misleading customers by "underfilling" its cold beverages. According to the plaintiff, Starbucks is cheating customers by serving cold coffees with too much ice cubes and less coffee than advertised, "often...
comments powered by Disqus
Follow RTT